Weight-loss drugs have been surging in popularity over the past year. Even Novo Nordisk's Ozempic, which isn't approved to treat weight loss, has made for a hot trend on social media, with people showing off their results from using the diabetes drug.

And now, there could soon be another weight-loss treatment that consumers may be able to use, and it's from (NYSE: PFE).

A peer-reviewed study has recently come out on Pfizer's weight-loss treatment, danuglipron. And the study, which is based on phase 2 trial data, is encouraging. Patients with type 2 diabetes who took the pill twice daily lost an average of 10 pounds during a period of 16 weeks.

Continue reading

Source Fool.com